An open-label, randomized, phase 3 trial of Nivolumab vs Investigator's choice chemotherapy as first-line therapy for stge IV or recurrent PD-L1+non-small cell lung cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
February 1, 2014
End Date
June 1, 2022
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
February 1, 2014
End Date
June 1, 2022